Liu G S, Richards S C, Olsson R A, Mullane K, Walsh R S, Downey J M
Department of Physiology, University of South Alabama, Mobile 36688.
Cardiovasc Res. 1994 Jul;28(7):1057-61. doi: 10.1093/cvr/28.7.1057.
Agonists selective for the A1 adenosine receptor mimic the protective effect of ischaemic preconditioning against infarction in the rabbit heart. Unselective adenosine antagonists block this protection but, paradoxically, the A1 adenosine receptor selective antagonist 8-cyclopentyl- 1,3-dipropylxanthine (DPCPX) does not. The aim of this study was to test the hypothesis that the newly described A3 adenosine receptor, which has an agonist profile similar to the A1 receptor but is insensitive to DPCPX, might mediate preconditioning.
Isolated rabbit hearts perfused with Krebs buffer experienced 30 min of regional ischaemia followed by 120 min of reperfusion. Infarct size was measured by tetrazolium staining.
In control hearts infarction was 32.2(SEM 1.5)% of the risk zone. Preconditioning by 5 min ischaemia and 10 min reperfusion reduced infarct size to 8.8(2.3)%. Replacing the regional ischaemia with 5 min perfusion with 10 microM adenosine or 65 nM N6-[2-(4-aminophenyl)ethyl]adenosine (APNEA), an adenosine A3 receptor agonist, was equally protective. The unselective antagonist 8-p-sulphophenyl theophylline at 100 microM abolished protection by preconditioning, adenosine, and APNEA, but 200 nM DPCPX did not block protection by any of the interventions. Likewise the potent but unselective A3 receptor antagonist 8-(4-carboxyethenylphenyl)-1,3-dipropylxanthine (BW A1433) completely blocked protection from ischaemic preconditioning.
Because protection against infarction afforded by ischaemic preconditioning, adenosine, or the A3 receptor agonist APNEA could not be blocked by DPCPX and because the potent A3 receptor antagonist BW A1433 blocked protection from ischaemic preconditioning, these data indicate that the protection of preconditioning is not exclusively mediated by the adenosine A1 receptor in rabbit heart and could involve the A3 receptor.
对A1腺苷受体具有选择性的激动剂可模拟缺血预处理对兔心脏梗死的保护作用。非选择性腺苷拮抗剂可阻断这种保护作用,但矛盾的是,A1腺苷受体选择性拮抗剂8-环戊基-1,3-二丙基黄嘌呤(DPCPX)却不能。本研究的目的是检验以下假设:新描述的A3腺苷受体,其激动剂谱与A1受体相似但对DPCPX不敏感,可能介导预处理。
用 Krebs 缓冲液灌注的离体兔心脏经历30分钟的局部缺血,随后再灌注120分钟。通过四氮唑染色测量梗死面积。
在对照心脏中,梗死面积占危险区的32.2(标准误1.5)%。5分钟缺血和10分钟再灌注的预处理使梗死面积降至8.8(2.3)%。用10微摩尔腺苷或65纳摩尔N6-[2-(4-氨基苯基)乙基]腺苷(APNEA,一种腺苷A3受体激动剂)进行5分钟灌注替代局部缺血,具有同等的保护作用。100微摩尔的非选择性拮抗剂8-对磺基苯基茶碱消除了预处理、腺苷和APNEA的保护作用,但200纳摩尔DPCPX并未阻断任何一种干预措施的保护作用。同样,强效但非选择性的A3受体拮抗剂8-(4-羧基乙烯基苯基)-1,3-二丙基黄嘌呤(BW A1433)完全阻断了缺血预处理带来的保护作用。
由于缺血预处理、腺苷或A3受体激动剂APNEA所提供的抗梗死保护作用不能被DPCPX阻断,且强效A3受体拮抗剂BW A1433阻断了缺血预处理的保护作用,这些数据表明,兔心脏中预处理的保护作用并非仅由腺苷A1受体介导,可能涉及A3受体。